Benevolent Platform
benevolent.com
5.5 Club score Visit benevolent.com
What the maker publishes
- AI and data
- BenevolentAI describes its technology as using multimodal data to surface insights and accelerate biomedical discovery. source
- Audience
- BenevolentAI says its team supports scientists and executives using AI and machine learning in their work. source
- Collaborations
- The company names AstraZeneca and Merck among its pharmaceutical discovery collaboration partners. source
- Contact
- The company provides a press contact email address. source
- Drug discovery
- The company says it uses its platform, scientific expertise, and wet-lab facilities to accelerate novel drug discovery. source
- Focus
- In April 2024, BenevolentAI said it would focus on drug discovery collaborations and its proprietary pipeline. source
- Founded
- 2013 source
- Founded
- BenevolentAI's press kit lists 2013 as its founding year. source
- Headquarters
- London, UK source
- Headquarters
- The company describes itself as headquartered in London. source
- Knowledge Exploration Tools
- The company announced that work on its Knowledge Exploration Tools would cease after a market assessment. source
- Knowledge graph
- The company says its technology builds on investment in a knowledge graph and proprietary ontologies. source
- Platform development
- A 2024 company announcement stated that investment would continue in development of the BenevolentAI Platform. source
- Platform offering
- BenevolentAI describes its platform as integrating AI and science to uncover new biology, predict novel targets, and develop drugs for complex diseases. source
- Product availability
- The current homepage presents Qor as an always-on strategic function for biopharma decision makers and life science consultancies. source
Checked against the maker's pages on 14 Nov 2026.